EASIX-GVHD score in patients with acute GVHD after allogenic stem-cell transplantation
Endothelial dysfuntion links thrombotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. The Endothelial Activation and Stress Index (EASIX) calculates the risk of death in patients with acute GVHD after allogeneic stem-cell transplantation.
Research authors: Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, Sandmaier BM, Becker N, Radujkovic A, Dreger P, and Penack O.
Version: 1.7
  • Details
  • Validate model
  • Save input
  • Load input

Calculate the result

Set more parameters to perform the calculation

The EASIX-GVHD score is: points

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Context information:
The present clinical application of EASIX-GVHD is an easy-to-use prediction of acute GVHD mortality in patients who have undergone RIC alloSCT, raising awareness of the endothelial nature of the problem. The tool provides a tool for studies with these therapeutic approaches and could be the future basis for development of risk-adapted GVHD treatment strategies. The EASIX-GVHD score, measured at the onset of acute GVHD, can be applied to predict overall and non-relapse mortality in patients with GVHD who had undergone reduced-intensity conditioning (RIC).

Model validation: 
The EASIX-GVHD model was based on a training cohort of 311 patients and subsequently validated on the Berlin, Seattle, and Cincinnati cohorts (external validation). 
A prospecitve validation study for the EASIX-GVHD is underway. To address another possible clinical application, the authors of the orignal EASIX-GVHD are currently performing retrospective analyses of EASIX taken before start of conditioning as a predictor of alloSCT outcome.

References: 
Luft T, Benner A, Jodele S, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017. pii: S2352-3026(17)30108-4.

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This model is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}


Evidencio Community Account Benefits


With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.


Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved